Europe Breast Lesion Localization Methods Market is expected to register a CAGR of healthy rate in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Access Full Report at https://databridgemarketresearch.com/reports/europe-breast-lesion-localization-methods-market

Drivers: Europe Breast Lesion Localization Methods Market

Technological Advancements In Breast Localization:

Breast localization is playing significant role in detecting or marking the tumors or lumps in the breasts. The method of localization is widely used in the treatment of breast cancer detection. Much technological advancement had taken place in the localization of non-palpable breast lesions as there had been innovative technologies.

• Elucent Medical has Smartclip and Envisio detection system which is an advanced systems which eliminates the wire and radiation localizations procedures.
• Cianna Medical has SAVI SCOUT, which is designed to detects the breast cancers using radar for a zero-radiation and wire-free solution designed to aid surgeons in locating target tissue.

Rising Prevalence Of Breast Cancer and Increasing Breast Cancer Surgeries:

Breast cancer is the most common and offensive cancer in women. The changing lifestyle in women such as increased urbanization, rise in obesity and inactive ways of living and delayed childbirths leads to breast cancer. 

• According to Cancer Research Organization UK, in 2014, 54,833 female cases are registered in UK.
• According to National Cancer Institute, of all cancer cases 15.0% represent the female breast cancer amongst common types of cancers.
• According to National Cancer Institute, in 2014 approximately 3,327,552 women living with female breast cancer in the U.S.
• According to Breast Cancer India, 232,714 women in U.S., 187,213 in China and 144,937 in India were detected with breast cancer.

Restraints:

Regulatory Scenarios in Breast Localization:

• Regulations play an important role in healthcare arena, in case of product approval, product recall and patients’ safety. Regulations in breast cancer surgeries are more inclined towards the safety of women and their health. Radioactive seed localization (RSL), is the new approach towards breast localization over wire localization. In 2006, the first guidance regarding RSL was issued by the NRC. The seed or seeds used in RSL are of non-palpable breast lesions are disposed of in accordance with 10 CFR 35.92 or the equivalent Agreement-State regulations.
• FDA also recalled some products from the market due its inefficiency in manufacturing and due to safety regarding to patients’ health. For instance, FDA recalled Kopans Breast Lesion Localization Needle of Cook from market due to its potential to expose to body fluids during processing.

PRODUCT RECALL:

Product recall is the procedure to recall the launched product from the market due to frequent causes related to device design, software, and non-conforming material or component issues and issues concerning to the safety of patients. Therefore, recall poses a significant challenge for the medical device industry.

Various products are recalled from the market by FDA due to various reasons such as manufacturing defects or patients’ safety. Following are some products which are recalled by FDA:

• Medical Device Technologies, Inc., business as Angiotech recalled the product of Angiotech breast localization needles due to packaging integrity.
• Cook product Kopans Breast Lesion Localization Needle was recalled due to its potential to expose to body fluids during processing.

Opportunity:

EMERGING MARKET:

Breast cancer is the most prevailing disease in the women due to various factors such as urbanization, delayed childbirths and inactive ways of living leads to breast cancer. The several cancer cases are recorded in the developing several Asian countries.

In Asia-Pacific region, 24.0% of cancers were diagnosed of all breast cancer cases in the world. In which China accounts 46.0%, Japan accounts 14.0% and Indonesia 12.0%. The highest rate of breast cancer for East Asia occurred in Japan and South Korea and South East Asia the highest rate was occurred in Singapore.

Challenge:

RISK ASSOCIATED WITH THE BREAST SURGERY AND PAINFUL CONSEQUENCES:

Breast surgeries include breast reduction surgery, augmentation mammoplasty, mastectomy, breast reconstruction, breast localization and many others. Many risks and side-effects are associated with breast surgeries which hampers the growth of market. Consequences such as adverse reactions of the needles or injection in the process of localization, occasionally left fragments of wire in the breast after surgery, wire dislodgement and breast biopsies has the risks of bruising, infection and hematoma. Many post breast surgery has the issues such as problems with the anesthesia, bleeding, blood clots, wound healing problems and others.

The risks and consequences after the breast surgeries are hampering the growth of the market.

Market Trends:

Europe breast lesion localization methods market is segmented based on type, Biopsy Techniques and end user.

• On the basis of type, the market is segmented into wire localization, radioisotope localization, magnetic tracers and others. The radioisotope localization is further sub segmented into radioactive seed localization and radio occult lesion localization. In 2017, wire localization segment is projected to lead with the shares 38.0% and will CAGR of 12.1%. However, magnetic tracers segment is growing with the highest CAGR of 12.9% in the forecast period of 2018 to 2025.
• On the basis of end user, the market is segmented into hospitals, oncology clinics, diagnostic centers and ambulatory surgical centers. In 2017, hospitals segment is projected to lead with the shares 36.5% and will attain the highest CAGR of 13.0% in the forecast period of 2018 to 2025.

Major Players: Europe Breast Lesion Localization Methods Market

Some of the major players operating in the market are ARGON MEDICAL, Cook Group, C. R. Bard, Inc. and others.